Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure A Report on Behalf of the MDS Clinical Research Consortium

BACKGROUND: The hypomethylating agents (HMAs) azacitidine and decitabine are most commonly used to treat patients with higher-risk myelodysplastic syndromes (MDS). To the authors' knowledge, the prognosis of patients with low-risk and intermediate-1– risk MDS by the International Prognostic Sco...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer
Main Authors: Jabbour, Elias J., Garcia-Manero, Guillermo, Strati, Paolo, Mishra, Asmita, Al Ali, Najla H., Padron, Eric, Lancet, Jeffrey, Kadia, Tapan, Daver, Naval, O'Brien, Susan, Steensma, David P., Sekeres, Mikkael A., Gore, Steven D., Dezern, Amy, Roboz, Gail J., List, Alan F., Kantarjian, Hagop M., Komrokji, Rami S.
Format: Artigo
Sprog:Inglês
Udgivet: 2014
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4378905/
https://ncbi.nlm.nih.gov/pubmed/25410759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29145
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker